Comparison of the efficacy of ondansetron alone versus ondansetron and dexamethasone in the prevention of nausea and vomiting in patients with airway surgical procedures

Comparison of the efficacy of ondansetron alone versus ondansetron and dexamethasone in the prevention of nausea and vomiting in patients with airway surgical procedures - Comparison of the efficacy of ondansetron alone versus ondansetron and dexamethasone in the prevention of nausea and vomiting in patients with airway surgical procedures

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000054369

Enrollment

130

Registered

2024-05-10

Start date

2024-05-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing minor oral surgery under general anesthesia(except orthognathic surgery and malignant tumor surgery and nerve repair)

Interventions

The ondansetron alone group will receive 2ml of saline as the study drug after the end of intubation. The ondansetron and dexamethasone group will receive 6.6mg(2ml) of dexamethasone as the study drug

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eligible patients meet the criteria of the ASA-PS of 1-2. Patient who gave consent for this study

Exclusion criteria

Exclusion criteria: Under 20 years and over 51 years of age, ASA-PS3 or higher, patient consent not obtained, use of antiemetics within 24h before surgery, contraindicated for administration of medications used in this study, emergency surgery

Design outcomes

Primary

Measure	Time frame
Incidence of ponv(early stage:2 hours after the end of anesthesia, last stage:2~24 hours after the end of anesthesia)	—

Secondary

Measure	Time frame
Patient background (age, gender, height, weight, smoking history, and presence or absence of motion sickness/ PONV), surgical and anesthetic factors (operation name, operation time, anesthesia time, total infusion volume, blood loss, intraoperative opioid use, and postoperative opioid use), and (amount of opioid use, postoperative opioid use or not), degree of PONV (NRS maximum value (early: up to 2 hours after the end of anesthesia, late: 2~24 hours after the end of anesthesia), the degree of PONV, and the degree of PONV) ~(age, sex, height, weight, smoking history, history of motion sickness/PONV), presence or absence of vomiting up to 24 hours after the end of anesthesia, number of metoclopramide doses administered, and the number of times the (number of patients), Quality of postoperative recovery(QoR-40).	—

Measure

Time frame

Patient background (age, gender, height, weight, smoking history, and presence or absence of motion sickness/ PONV), surgical and anesthetic factors (operation name, operation time, anesthesia time, total infusion volume, blood loss, intraoperative opioid use, and postoperative opioid use), and (amount of opioid use, postoperative opioid use or not), degree of PONV (NRS maximum value (early: up to 2 hours after the end of anesthesia, late: 2~24 hours after the end of anesthesia), the degree of PONV, and the degree of PONV) ~(age, sex, height, weight, smoking history, history of motion sickness/PONV), presence or absence of vomiting up to 24 hours after the end of anesthesia, number of metoclopramide doses administered, and the number of times the (number of patients), Quality of postoperative recovery(QoR-40).

—

Countries

Japan

Contacts

Public ContactRika Nomura

Tokyo Dental College Dental Anesthesiology

nomurarika@tdc.ac.jp03-6380-9001

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026